530799 | AGE Inhibitor, LR-90 - Calbiochem

530799
価格が見つかりません
Minimum Quantity needs to be mulitiple of
弊社照会 詳細を表示 
値引
()
 
弊社照会
現在国内在庫なし現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      価格&在庫状況を照会
      クリックして印刷用に表示

      概要

      Replacement Information

      主要スペック表

      Empirical Formula
      C₃₅H₃₄Cl₂N₄O₈

      価格&在庫状況

      カタログ番号在庫状況 包装 Qty/Pk 価格 数量
      5.30799.0001
      在庫状況検索中…
      現在国内在庫なし現在国内在庫なし
      現在国内在庫有り 
      販売中止
      在庫僅少
      現在国内在庫あり
        Remaining : Will advise
          Remaining : Will advise
          注文対象外
          お問合せください

          ガラスビン 10 mg
          価格を検索中…
          価格が見つかりません
          Minimum Quantity needs to be mulitiple of
          弊社照会 詳細を表示 
          値引
          ()
           
          弊社照会
          Description
          OverviewA cell-permeable methylene bisphenylureido derived compound that blocks the formation of advanced glycation endproduct (AGE) by scavenging dicarbonyl intermediates and by chelating transition metals that catalyze the production of AGE. Inhibits metal ion-catalyzed oxidation of ascorbate (IC50 = 275 µM). Exhibits protective effects against diabetic nephropathy, retinopathy, and atherosclerosis and reduces arterial stiffness in diabetic animals (~50 mg/L drinking water) by reducing collagen accumulation and cross-linking. Although it does not affect glycemic condition and body weight in normal and diabetic animals, it reduces plasma triglycerides and glycated hemoglobin levels in diabetic rats and improves their cardiac output and stroke volume. Also shown to suppress S100b and TNFa-induced activation of NF-κB.

          Please note that the molecular weight for this compound is batch-specific due to variable water content.
          Catalogue Number530799
          Brand Family Calbiochem®
          SynonymsAdvanced Glycation Endproducts Inhibitor
          References
          ReferencesSatheesan, S., et al. 2014. Br. J. Pharmacol. 171, 3103.
          Nagai, R., et al. 2012. Diabetes. 61, 549.
          Figarola, J.L., et al. 2008. Diabetologia. 51, 882.
          Figarola, J.L., et al. 2003. Diabetologia. 46, 1140.
          Product Information
          FormOff-white powder
          Hill FormulaC₃₅H₃₄Cl₂N₄O₈
          Chemical formulaC₃₅H₃₄Cl₂N₄O₈
          Applications
          Biological Information
          Primary Target=IF(SGM_MetricTransfer!C11=,,SGM_MetricTransfer!C11)
          Purity≥97% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          (M)SDS

          タイトル

          英語版製品安全データシート((M)SDS) 

          参考資料

          参考資料の概要
          Satheesan, S., et al. 2014. Br. J. Pharmacol. 171, 3103.
          Nagai, R., et al. 2012. Diabetes. 61, 549.
          Figarola, J.L., et al. 2008. Diabetologia. 51, 882.
          Figarola, J.L., et al. 2003. Diabetologia. 46, 1140.
          データシート

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision08-August-2014 JSW
          SynonymsAdvanced Glycation Endproducts Inhibitor
          DescriptionA cell-permeable methylene bisphenylureido derived compound that blocks the formation of advanced glycation endproduct (AGE) by scavenging dicarbonyl intermediates and by chelating transition metals that catalyze the production of AGE. Inhibits metal ion-catalyzed oxidation of ascorbate (IC50 = 275 µM). Exhibits protective effects against diabetic nephropathy, retinopathy, and atherosclerosis and reduces arterial stiffness in diabetic animals (~50 mg/L drinking water) by reducing collagen accumulation and cross-linking. Although it does not affect glycemic condition and body weight in normal and diabetic animals, it reduces plasma triglycerides and glycated hemoglobin levels in diabetic rats and improves their cardiac output and stroke volume. Also shown to suppress S100b and TNFa-induced activation of NF-kB.
          FormOff-white powder
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₃₅H₃₄Cl₂N₄O₈
          Purity≥97% by HPLC
          SolubilityDMSO (100 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesSatheesan, S., et al. 2014. Br. J. Pharmacol. 171, 3103.
          Nagai, R., et al. 2012. Diabetes. 61, 549.
          Figarola, J.L., et al. 2008. Diabetologia. 51, 882.
          Figarola, J.L., et al. 2003. Diabetologia. 46, 1140.